Authorization process for the Russian vaccine Sputnik V,

Reading time: 2 minutes

The approval procedure by the European Medicines Agency (EMA) for the Russian vaccine against COVID-19 Sputnik V has been suspended indefinitely due to lack of contact with Russian officials, a representative of the European institution announced on Thursday, quoted by DPA .

“There is currently no joint activity and no contact with the Russian authorities,” said Fergus Sweeney, director of the EMA’s clinical trials department. “We do not anticipate a resumption of the procedure in the near future,” he added, according to AGERPRES.

Sputnik V was the first vaccine launched on the market against the new coronavirus.

However, questions about its effectiveness and a number of irregularities in its authorization process in Russia have caused controversy around this serum, and other COVID-19 vaccines, launched many months after Sputnik V, have already been approved. and are widely used in the European Union.

It is unknown at this time what he will do after leaving the post with Russian officials.

The EMA began examining the specifics of the Sputnik V vaccine a year ago as part of its authorization process for medical products. The procedure involves examining medical data from studies and tests, even if no official application for EU authorization has been submitted. The general principle is to speed up the authorization procedure.

Evaluation of the Sputnik V vaccine has been postponed several times due to the lack of important medical data. Russian serum has been approved for use in Russia and several non-EU countries.